Jun 11, 2025, 08:22
Mastering the Art of Platelet Transfusion: Dr. Akhil Breaks Down the Clinical Thresholds You Need to Know
In a recent insightful post on X, Dr. Akhil delivers a concise yet powerful breakdown of platelet transfusion thresholds—a critical guide for clinicians navigating invasive procedures in patients with thrombocytopenia.
“When will you want to transfuse platelets?
Typical Recommended Platelet Count Thresholds for Common Procedures
Platelet transfusion may be considered when the patient’s platelet count is below the threshold for the corresponding procedure.
Neurosurgery or ocular surgery – <100,000/microL
Most other major surgery – <50,000/microL
Endoscopic procedures – <50,000/microL for therapeutic procedures; 20,000/microL for low risk diagnostic procedures
Bronchoscopy with bronchoalveolar lavage (BAL) – <20,000 to 30,000/microL
Central line placement – <20,000/microL
Lumbar puncture – <10,000 to 20,000/microL in patients with hematologic malignancies and <40,000 to 50,000 in patients without hematologic malignancies; lower thresholds may be used in patients with immune thrombocytopenia (ITP)
Neuraxial analgesia/anesthesia – <80,000/microL
Bone marrow aspiration/biopsy – <20,000/microL
Actively bleeding patients with thrombocytopenia should be transfused with platelets immediately to keep platelet counts >50,000/microL in most bleeding situations including disseminated intravascular coagulation (DIC), and >100,000/microL if there is central nervous system bleeding
Source : UpToDate”
Remember: Actively bleeding patients require immediate transfusion. Timely action can be lifesaving, especially in cases of CNS bleeding or DIC.”
See the full breakdown and expert commentary now on Hemostasis Today.
-
Oct 28, 2025, 14:27Maha Othman on 10-Year Anniversary of the CanVECTOR Research Network!
-
Oct 28, 2025, 14:00Claudio Laudani on PCSK9 Association with Increased Platelet Reactivity: A Pooled Analysis
-
Oct 28, 2025, 13:31Laurent Bertoletti Invites You to The INNOVTE and GITA Joined Meeting on Hormones and Thrombosis
-
Oct 28, 2025, 12:28Courtney Lawrence: Honored to Team Up with BET on Blood at AABB 2025
-
Oct 27, 2025, 19:45Benedikt Lorenz on Liver Failure and Coagulation – Myths, Traps, and Bad Habits
-
Oct 28, 2025, 13:09Gregory Piazza on CORONA-VTE Network Analysis
-
Oct 27, 2025, 18:42Khaled Musallam Shares BEYOND Trial Phase 2 Insights on Luspatercept Use in NTD β-Thalassaemia
-
Oct 27, 2025, 13:30Fabrice Cognasse: When Platelets Meet Artificial Intelligence!
-
Oct 27, 2025, 13:00Hossam El Benawi Shares Multi Site LVT Study from Mayo Clinic
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 15:10David McIntosh: Making Measurable Progress – Towards a World in Which No-one Ever Dies from Lack of a Vital Plasma-Derived Medicine
-
Oct 27, 2025, 13:18Stroke Foundation Welcomes Jacqui McCallum as the New Executive Director
-
Oct 27, 2025, 12:54Guillermo Lahera Forteza on Stroke and Mental Health
-
Oct 27, 2025, 12:37Joshua Ngimbwa Recognised as the Best Male Junior Investigator Awardee at the Tanzania Health Summit
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
Oct 28, 2025, 14:27
Oct 28, 2025, 13:09
Oct 28, 2025, 12:28
Oct 27, 2025, 14:33
Oct 27, 2025, 13:30
Oct 27, 2025, 13:18
Oct 27, 2025, 13:00